Why the study?
Although LV reverse remodeling occurs after septal myectomy in HOCM, whether diffuse myocardial fibrosis is reversible during this period remained unclear.
Does septal myectomy improve diffuse myocardial fibrosis and clinical parameters in patients with hypertrophic obstructive cardiomyopathy?
Does septal myectomy improve diffuse myocardial fibrosis and clinical parameters in patients with hypertrophic obstructive cardiomyopathy?
Septal myectomy in HOCM patients is associated with reversibility of cellular hypertrophy and diffuse fibrosis at 6 months, alongside improvements in exercise capacity and cardiac biomarkers, though focal fibrosis does not regress.
Answers are grounded in this paper and cite their sources.
Symptomatic gains post-myectomy may not reflect reduced fibrosis; leaves open remodeling effects on long-term HOCM outcomes.
BACKGROUND: Left ventricular (LV) reverse myocardial remodeling occurs following septal myectomy in hypertrophic obstructive cardiomyopathy (HOCM), but it remains unclear whether diffuse fibrosis is reversible during this period. Extracellular volume fraction (ECV) and indexed extracellular volume (iECV) are important surrogate markers of diffuse myocardial fibrosis. This study aimed to investigate whether diffuse myocardial fibrosis in HOCM can regress after myectomy. METHODS: A prospective cohort study was conducted among patients with HOCM. All subjects underwent clinical assessment (clinical history, 6-min walk test, biochemical analysis), echocardiography, and cardiovascular magnetic resonance preoperatively and 6months after septal myectomy. RESULTS: ; p<0.001). Conversely, ECV (28.2±3.3% to 30.2±2.8%; p<0.001) and late gadolinium enhancement mass (4.5 [0.2-8.2]g to 8.7 [2.1-12.8]g; p<0.001) increased. These changes were accompanied by improvement of New York Heart Association functional class, 6-min walk test results, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T. CONCLUSION: Six months after septal myectomy, both cellular hypertrophy and diffuse fibrosis are reversible in HOCM, while focal fibrosis does not regress. These changes are accompanied by improvement of exercise parameters and laboratory biomarkers, revealing the plastic nature of diffuse fibrosis in HOCM and its potential as a therapeutic target.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: